Polyphenol Metabotypes in People With Diabetes Type 2

Polyphenol Metabotypes in People With Diabetes Type 2

This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).

Inclusion Criteria:

• all participants
• between 40-85 years
• age-matched individuals without diabetes
• BMI between 18.5-30
• no metabolic syndrome
• persons with T2DM
• at leats 2 years of clinical diagnoses of T2DM
• stable medication use for at least 1 month

Exclusion Criteria:

• pregnancy of breastfeeding
• in last month
• acute use of anti/pre/probiotics
• start of new drug or dietary supplements
• major changes in diet
• major lifestyle changes
• diseases
• Gastrointestinal diseases (inflammatory bowel disease)
• Bariatric surgery
• Other forms of diabetes (cystic fibrosis/MODY/T1DM)
• Heart problems (NYHA 3/4) or previous cardiovascular events
• Liver problems: non-alcohol steatohepatitis (NASH) and cirrhosis
• Lung problems (COPD - GOLD 3/4), cystic fibrosis
• Uncontrolled thyroid function disruption in the past 6 months
• Intake of coumarin derivatives and direct oral anticoagulant medication
• Anti-cancer treatment: chemo-/immunotherapy
• Immonosuppressants (transplant)
• Antiepileptic drugs